A potentially severe side effect, angioedema (rapid swelling of deeper skin tissues as well as the tissues around the throat, causing breathing difficulty) can occur uncommonly (in up to 1 in 100 people). The most common side effects with Entresto in adults (which may affect more than 1 in 10 people) include hyperkalaemia (high blood potassium levels), hypotension (low blood pressure) and renal impairment (kidneys working less well). What are the risks associated with Entresto?įor the full list of side effects and restrictions with Entresto, see the package leaflet. However, in both the Entresto and enalapril groups, there were relevant improvements in symptoms and quality of life measures. The results did not show that Entresto was more effective than enalapril in terms of this measure. The main measure of effectiveness was the likelihood of a better outcome after one year of treatment compared with that in the other treatment group (based on the ranking of various events such as death, urgent heart transplant or worsening of symptoms). In addition, the study compared Entresto with enalapril in 377 patients aged 1 month to below 18 years with heart failure due to systemic left ventricle systolic dysfunction. A reduced level of NT-proBNP is associated with a better outcome for patients. Patients with heart failure have raised levels of NT-proBNP, substances made by the heart. In addition, Entresto led to similar reductions across age groups in the blood levels of NT-proBNP. The study was stopped early because there was compelling evidence that Entresto was more effective than enalapril.Ī study involving children and adolescents showed that the way Entresto behaves in the body in people below 18 years old is similar to that seen in adults. In general, patients were monitored for about 27 months, during which they took the medicine for about 24 months on average. In the group treated with Entresto, 21.8% (914 of 4,187) of patients either died as a result of heart and circulation problems or were admitted to hospital with heart failure compared to 26.5% (1,117 of 4,212) of patients treated with enalapril. ![]() ![]() Patients in the study had long-term heart failure with symptoms of the disease and reduced ejection fraction (the proportion of blood leaving the heart). In the study, Entresto was compared to enalapril, another medicine used for heart failure. Entresto has been shown to be effective at treating heart failure in adults in one main study.
0 Comments
Leave a Reply. |